Measurable residual disease (MRD) monitoring has greatly improved therapeutic decision making in cases of PML-RARα-positive APL, however, data regarding MRD monitoring in patients with the STAT5B-RARα rearrangement is very limited. Here, RARA is linked to acute promyelocytic leukemia.